Your browser doesn't support javascript.
loading
Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands.
van den Heuvel, Jan Maurik; Farzan, Niloufar; van Hoek, Mandy; Maitland-van der Zee, Anke-Hilse; Ahmadizar, Fariba.
Affiliation
  • van den Heuvel JM; Department of Respiratory Disease, Academic Medical Center, Amsterdam, The Netherlands maurik.vandenheuvel@breathomix.com f.ahmadizar@erasmusmc.nl.
  • Farzan N; Department of Respiratory Disease, Academic Medical Center, Amsterdam, The Netherlands.
  • van Hoek M; Department of Internal Medicine, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands.
  • Maitland-van der Zee AH; Department of Respiratory Disease, Academic Medical Center, Amsterdam, The Netherlands.
  • Ahmadizar F; Department of Epidemiology, Erasmus University, Rotterdam, Zuid-Holland, The Netherlands maurik.vandenheuvel@breathomix.com f.ahmadizar@erasmusmc.nl.
Article in En | MEDLINE | ID: mdl-31958296
ABSTRACT
RATIONALE AND

OBJECTIVES:

Different classes of glucose-lowering medications are used for patients with type 2 diabetes mellitus (T2DM) management. It is unclear how often these medications are prescribed in clinical practice. In this study, we aimed to describe treatment patterns of glucose-lowering medications in patients with T2DM in the Netherlands.

METHODS:

We studied a cohort of 73 819 patients with T2DM, aged ≥45 years with a first prescription for oral glucose-lowering medication between 2011 and 2017. We used the NControl database with dispensing data from 800 pharmacies in the Netherlands. Prevalence of each glucose-lowering medication class during 6 years after the index date was calculated. Using SQL Server, we identified stepwise patterns of medication prescription in this population.

FINDINGS:

During the study period, prevalence of biguanides (BIGU) decreased from 95.6% to 80.8% and use of sulfonylureas (SU) increased from 27.3% to 42.3%. 55.2% of all patients only received BIGUs, 19.1% of all patients started on BIGUs but switched to BIGU +SU. 13.5% of patients with T2DM initiated insulins, on average 532 days (almost 18 months) after the index date.

CONCLUSIONS:

Our findings showed that in the Netherlands, medication treatment in patients with T2DM is mainly consistent with the clinical guidelines in the Netherlands during the study period.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfonylurea Compounds / Biguanides / Blood Glucose / Diabetes Mellitus, Type 2 / Hypoglycemic Agents / Insulin Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: BMJ Open Diabetes Res Care Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfonylurea Compounds / Biguanides / Blood Glucose / Diabetes Mellitus, Type 2 / Hypoglycemic Agents / Insulin Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: BMJ Open Diabetes Res Care Year: 2020 Document type: Article